{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:56:42Z","timestamp":1791475002904,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.medcli.2020.12.025","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T17:05:35Z","timestamp":1616259935000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of renin\u2013angiotensin\u2013aldosterone system blockade in controversial chronic kidney disease populations"],"prefix":"10.1016","volume":"156","author":[{"given":"Ana Mar\u00eda","family":"Garc\u00eda-Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00darsula","family":"Verdalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.12.025_bib0300","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.ki.5002343","article-title":"Chronic kidney disease as a global public health problem: approaches and initiatives \u2013 a position statement from Kidney Disease Improving Global Outcomes","volume":"72","author":"Levey","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.medcli.2020.12.025_bib0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2020.12.025_bib0315","doi-asserted-by":"crossref","unstructured":"Summary of Recommendation Statements. Kidney Int Suppl 2020;2:341\u20132.","DOI":"10.1038\/kisup.2012.50"},{"key":"10.1016\/j.medcli.2020.12.025_bib0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0325","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0330","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/030079908X291921","article-title":"Angiotensin receptor blockers: RAAS blockade and renoprotection","volume":"24","author":"Ruilope","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medcli.2020.12.025_bib0335","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0340","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0345","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0350","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0355","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0360","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2840-1-2","article-title":"Losartan and diabetic nephropathy: commentaries on the RENAAL study","volume":"1","author":"Fisman","year":"2002","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0370","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin\u2013angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0375","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5527\/wjn.v4.i1.118","article-title":"Time to re-evaluate effects of renin\u2013angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy","volume":"4","author":"Suzuki","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0380","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2020.12.025_bib0385","doi-asserted-by":"crossref","first-page":"e0170874","DOI":"10.1371\/journal.pone.0170874","article-title":"The impact of renin\u2013angiotensin system blockade on renal outcomesand mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medcli.2020.12.025_bib0390","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11255-006-0084-4","article-title":"Acute renal failure in the elderly: particular characteristics","volume":"38","author":"Musso","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0395","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7326\/0003-4819-150-10-200905190-00014","article-title":"Does evidence support renin\u2013angiotensin system blockade for slowing nephropathy progression in elderly persons?","volume":"150","author":"Sarafidis","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0400","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin\u2013angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2020.12.025_bib0405","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin\u2013angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2020.12.025_bib0410","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0272-6386(88)80086-6","article-title":"Effect of lisinopril monotherapy on renal hemodynamics","volume":"11","author":"Reams","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2020.12.025_bib0415","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin converting enzyme inhibitors: how much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0425","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"Gruppo Italiano di Studi Epidemiologici in Nefrologia ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0430","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0435","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3\u20135: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.medcli.2020.12.025_bib0440","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2020.12.025_bib0445","first-page":"462","article-title":"Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience","volume":"11","author":"Onuigbo","year":"2005","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.medcli.2020.12.025_bib0450","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/qjmed\/hcn039","article-title":"Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis","volume":"101","author":"Onuigbo","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.medcli.2020.12.025_bib0455","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin\u2013angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0460","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl. 2","key":"10.1016\/j.medcli.2020.12.025_bib0465","doi-asserted-by":"crossref","first-page":"ii194","DOI":"10.1093\/ndt\/gfw440","article-title":"Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease","volume":"32","author":"Bolignano","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2020.12.025_bib0470","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.medcli.2020.12.025_bib0475","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/qjmed\/94.2.89","article-title":"Randomized placebo-controlled trial of perindopril in normotensive, noromoalbuminuric patients with type 1 diabetes mellitus","volume":"94","author":"Kvetny","year":"2001","journal-title":"Q J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0485","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1681\/ASN.2004080634","article-title":"Antihypertensive agents for primary prevention of diabetic nephropathy","volume":"16","author":"Strippoli","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0490","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0495","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0195-668X(02)00797-2","article-title":"Outcome beyond blood pressure control?","volume":"24","author":"Staessen","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2020.12.025_bib0500","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2215\/CJN.02231205","article-title":"Progression of renal disease: renoprotective specificity of renin\u2013angiotensin system blockade","volume":"1","author":"Griffin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0510","doi-asserted-by":"crossref","unstructured":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253\u20139.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"10.1016\/j.medcli.2020.12.025_bib0515","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0520","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.12.025_bib0525","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.medcli.2020.12.025_bib0530","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","article-title":"Prevalence of chronic kidney disease in population-based studies: systematic review","volume":"8","author":"Zhang","year":"2008","journal-title":"BMC Public Health"},{"key":"10.1016\/j.medcli.2020.12.025_bib0535","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2005090986","article-title":"Mortality risk stratification in chronic kidney disease: one size for all ages?","volume":"17","author":"O\u2019Hare","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2020.12.025_bib0540","doi-asserted-by":"crossref","unstructured":"O\u2019Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150:717-24.","DOI":"10.7326\/0003-4819-150-10-200905190-00010"},{"key":"10.1016\/j.medcli.2020.12.025_bib0545","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0550","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithel","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.medcli.2020.12.025_bib0555","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0560","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0570","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial","volume":"31","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2020.12.025_bib0575","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.12.025_bib0580","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1001\/jama.2016.7070","article-title":"SPRINT results in older patients: how low to go?","volume":"315","author":"Chobanian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2020.12.025_bib0585","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","article-title":"Use of renin angiotensin system blockade in advanced CKD: an NKF-KDOQI controversies report","volume":"72","author":"Weir","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2020.12.025_bib0590","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/jgs.13842","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers in elderly adults with chronic kidney disease without diabetes mellitus or proteinuria","volume":"63","author":"Arora","year":"2015","journal-title":"J Am Geriatr Soc"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775321000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775321000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T19:49:52Z","timestamp":1672343392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775321000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0025775321000713"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.12.025","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of renin\u2013angiotensin\u2013aldosterone system blockade in controversial chronic kidney disease populations","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}